X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/21/2850042/0/en/Bionomics-Reports-Results-of-the-Full-Dataset-Analysis-from-ATTUNE-Phase-2b-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder.html
https://www.globenewswire.com//news-release/2024/02/22/2834124/0/en/Bionomics-to-Present-at-the-2024-BIO-CEO-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/01/22/2812832/0/en/Bionomics-Provides-a-Review-of-2023-and-of-2024-Plans.html
https://www.globenewswire.com//news-release/2024/01/05/2804526/0/en/Bionomics-to-Present-at-Biotech-Showcase-2024.html
https://www.globenewswire.com/news-release/2023/12/06/2791725/0/en/Bionomics-Presents-Detailed-Data-on-the-Validity-and-Reliability-of-the-Subjective-Units-of-Distress-Scale-at-the-2023-American-College-of-Neuropsychopharmacology-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/10/16/2760586/0/en/Bionomics-Announces-Successful-End-of-Phase-2-Meeting-with-the-FDA-and-Solidifies-Plans-to-Initiate-the-Registrational-Program-for-BNC210-in-Social-Anxiety-Disorder.html
https://www.fiercebiotech.com/biotech/bionomics-midphase-ptsd-clinical-trial-hits-primary-endpoint-doubling-its-battered-share
https://www.globenewswire.com//news-release/2023/09/28/2751004/0/en/Bionomics-Announces-Positive-Topline-Results-from-the-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html
https://www.globenewswire.com//news-release/2023/09/14/2743067/0/en/Bionomics-Announces-Update-on-the-%CE%B17-Nicotinic-Acetylcholine-Receptor-nAChR-Positive-Allosteric-Modulator-PAM-Collaboration-with-MSD.html
https://www.globenewswire.com//news-release/2023/08/23/2730217/0/en/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2b-ATTUNE-Study-for-Post-Traumatic-Stress-Disorder-PTSD-and-Confirms-Expected-2023-Milestones-with-its-Lead-Asset-BNC210.html
Market Place
Share 
